GlassScriptPhysician profile
Bruce L Belzer
NPI 1083666382
$2,913.58
in general payments reported to CMS, 2019-2025
35 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $269 · 2021: $114 · 2022: $232 · 2023: $459 · 2024: $568 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $414.43 | 2019-2024 | Farxiga |
| Amgen INC. | $380.72 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $336.90 | 2019-2025 | |
| Novo Nordisk INC | $261.04 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.35 | 2019-2024 | Jardiance, Synjardy |
| Abbvie INC. | $147.97 | 2019-2024 | Qulipta |
| Glaxosmithkline, LLC. | $132.24 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $122.67 | 2019-2024 | Jardiance, Emgality |
| Teva Pharmaceuticals USA, INC. | $80.76 | 2019-2024 | Ajovy |
| Allergan, INC. | $75.13 | 2019-2020 | |
| Exact Sciences Corporation | $72.11 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $66.16 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $55.40 | 2023-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $52.33 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.09 | 2019-2023 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $48.57 | 2019-2024 | Xyosted |
| Sanofi-Aventis U.S. LLC | $45.95 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.17 | 2019-2020 | |
| Genentech USA, INC. | $33.75 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.53 | 2023 | Hetlioz |
| Dynavax Technologies Corporation | $23.50 | 2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $22.54 | 2022 | |
| Medtronic USA, INC. | $20.47 | 2020 | |
| Halozyme INC | $20.18 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.81 | 2024 | Rexulti |
| Astellas Pharma US INC | $18.47 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $18.43 | 2019 | |
| Mylan Specialty L.P. | $16.95 | 2024 | Yupelri |
| Celgene Corporation | $16.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.11 | 2020 | |
| Amarin Pharma, INC. | $14.68 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Belzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.